These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 14506016)

  • 41. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults.
    Rodvold KA; Danziger LH; Gotfried MH
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2450-7. PubMed ID: 12878504
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics and pharmacodynamics of levofloxacin in intensive care patients.
    Sánchez Navarro A; Colino Gandarillas CI; Alvarez Lerma F; Menacho YA; Domínguez-Gil A
    Clin Pharmacokinet; 2005; 44(6):627-35. PubMed ID: 15910010
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Changes in cerebrospinal fluid hydrodynamics following endoscopic third ventriculostomy for shunt-dependent noncommunicating hydrocephalus.
    Nishiyama K; Mori H; Tanaka R
    J Neurosurg; 2003 May; 98(5):1027-31. PubMed ID: 12744362
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics of levofloxacin in Japanese quails (Coturnix japonica) following intravenous and oral administration.
    Aboubakr M
    Br Poult Sci; 2012; 53(6):784-9. PubMed ID: 23398423
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections.
    Furlanut M; Brollo L; Lugatti E; Di Qual E; Dolcet F; Talmassons G; Pea F
    J Antimicrob Chemother; 2003 Jan; 51(1):101-6. PubMed ID: 12493793
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Concentrations of ofloxacin in serum and cerebrospinal fluid of patients without meningitis receiving the drug intravenously and orally.
    Bitar N; Claes R; Van der Auwera P
    Antimicrob Agents Chemother; 1989 Oct; 33(10):1686-90. PubMed ID: 2589841
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects.
    Lee LJ; Hafkin B; Lee ID; Hoh J; Dix R
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2196-200. PubMed ID: 9333047
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials.
    Preston SL; Drusano GL; Berman AL; Fowler CL; Chow AT; Dornseif B; Reichl V; Natarajan J; Corrado M
    JAMA; 1998 Jan; 279(2):125-9. PubMed ID: 9440662
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis.
    Zeitlinger MA; Dehghanyar P; Mayer BX; Schenk BS; Neckel U; Heinz G; Georgopoulos A; Müller M; Joukhadar C
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3548-53. PubMed ID: 14576116
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics of levofloxacin after single intravenous and repeat oral administration to cats.
    Albarellos GA; Ambros LA; Landoni MF
    J Vet Pharmacol Ther; 2005 Aug; 28(4):363-9. PubMed ID: 16050816
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults.
    Capitano B; Mattoes HM; Shore E; O'Brien A; Braman S; Sutherland C; Nicolau DP
    Chest; 2004 Mar; 125(3):965-73. PubMed ID: 15006955
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges.
    Nau R; Prange HW; Muth P; Mahr G; Menck S; Kolenda H; Sörgel F
    Antimicrob Agents Chemother; 1993 Jul; 37(7):1518-24. PubMed ID: 8363385
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics of multiple intravenous instillation of levofloxacin in Chinese healthy subjects.
    Zhang L; Li JT; Lu Y; Li MN; Zhang YL; Liu Y; Li TY; Zhang JW
    Acta Pharmacol Sin; 2002 Apr; 23(4):381-4. PubMed ID: 11931699
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury.
    Kiser TH; Hoody DW; Obritsch MD; Wegzyn CO; Bauling PC; Fish DN
    Antimicrob Agents Chemother; 2006 Jun; 50(6):1937-45. PubMed ID: 16723549
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Translational Pharmacokinetic Rat Model of Cerebral Spinal Fluid and Plasma Concentrations of Cefepime.
    Avedissian SN; Pais G; Joshi MD; Rhodes NJ; Scheetz MH
    mSphere; 2019 Jan; 4(1):. PubMed ID: 30700511
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation by Monte Carlo simulation of levofloxacin dosing for complicated urinary tract infections caused by Escherichia coli or Pseudomonas aeruginosa.
    Deguchi T; Seike K; Yasuda M; Matsumoto T
    J Infect Chemother; 2011 Oct; 17(5):726-30. PubMed ID: 21409530
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500 mg b.i.d. for ventilator-associated pneumonia.
    Pea F; Pavan F; Di Qual E; Brollo L; Nascimben E; Baldassarre M; Furlanut M
    J Chemother; 2003 Dec; 15(6):563-7. PubMed ID: 14998081
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Steady-state pharmacokinetics of once-daily cyclobenzaprine extended release: a randomized, double-blind, 2-period crossover study in healthy volunteers.
    Darwish M; Hellriegel ET
    Clin Ther; 2011 Jun; 33(6):746-53. PubMed ID: 21704239
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid.
    Child J; Mortiboy D; Andrews JM; Chow AT; Wise R
    Antimicrob Agents Chemother; 1995 Dec; 39(12):2749-51. PubMed ID: 8593013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.